2025
Tumor microenvironment of non-small cell lung cancer impairs immune cell function among people with HIV
Desai S, Salahuddin S, Yusuf R, Ranjan K, Gu J, Osmani L, Lin Y, Mehta S, Talmon R, Kang I, Kluger Y, Zhao H, Schalper K, Emu B. Tumor microenvironment of non-small cell lung cancer impairs immune cell function among people with HIV. Journal Of Clinical Investigation 2025 PMID: 40459946, DOI: 10.1172/jci177310.Peer-Reviewed Original ResearchNon-small cell lung cancerTumor microenvironmentImmune cellsLung cancerCohort of non-small cell lung cancerExpression of PD-1Impairs anti-tumor responsesTumor-infiltrating CD8+Tumor-specific immune responsesCD4+ T cellsHIV-associated tumorsInfiltrating CD8+Expression of immunoregulatory moleculesAnti-tumor responsesTumor-associated macrophagesCell lung cancerImmune cell functionNSCLC cell linesPD-1Tumor killingBlocker therapyCD8+LAG-3Immune landscapeImmunoregulatory phenotypeCo-targeting of epigenetic regulators and BCL-XL improves efficacy of immune checkpoint blockade therapy in multiple solid tumors
Senent Y, Fresquet V, Jiménez V, Valencia K, Exposito F, Martín-Úriz P, Camps G, Fernández-Pierola E, de Córdoba B, González-Huarriz M, Tamayo I, Remírez A, Moreno H, Serrano D, Ajona D, Alonso M, Lecanda F, Pineda-Lucena A, Prósper F, Sanmamed M, Calvo A, Martinez-Climent J, Pio R. Co-targeting of epigenetic regulators and BCL-XL improves efficacy of immune checkpoint blockade therapy in multiple solid tumors. Molecular Cancer 2025, 24: 154. PMID: 40442785, PMCID: PMC12123720, DOI: 10.1186/s12943-025-02352-4.Peer-Reviewed Original ResearchConceptsImmune checkpoint blockadeBcl-xL inhibitorsBcl-xLSolid tumorsTumor cell linesHematologic malignanciesSolid tumor cell linesEfficacy of immune checkpoint blockade therapyEpigenetic regulationImmune checkpoint blockade therapyAnti-apoptotic protein Bcl-xLHuman colon cancer modelsPreclinical models of solid tumorsBCL-XL dependencyImmunosuppressive Treg cellsCheckpoint blockade therapyAnti-tumor responsesImmunogenic cell deathProlonged overall survivalProtein Bcl-xLColon cancer modelM1/M2 macrophage ratioMultiple solid tumorsModels of solid tumorsCell lines
2024
632 NC410 in combination with pembrolizumab improves anti-tumor responses by promoting collagen remodeling and tumor immunity in advanced ICI naïve MSS/MSI-L colorectal cancer (CRC)
Barbu A, Kothari P, Kahan S, Christenson E, Kazmi S, Manda S, Chisamore M, Kordahi S, Martz A, Nelson M, Morawski A, Flies D, Langermann S, Guha U, Myint H. 632 NC410 in combination with pembrolizumab improves anti-tumor responses by promoting collagen remodeling and tumor immunity in advanced ICI naïve MSS/MSI-L colorectal cancer (CRC). 2024, a727-a727. DOI: 10.1136/jitc-2024-sitc2024.0632.Peer-Reviewed Original ResearchNCF4 attenuates colorectal cancer progression by modulating inflammasome activation and immune surveillance
Li L, Mao R, Yuan S, Xie Q, Meng J, Gu Y, Tan S, Xu X, Gao C, Liu H, Ma C, Man S, Meng X, Xu T, Qi X. NCF4 attenuates colorectal cancer progression by modulating inflammasome activation and immune surveillance. Nature Communications 2024, 15: 5170. PMID: 38886341, PMCID: PMC11183137, DOI: 10.1038/s41467-024-49549-7.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsCARD Signaling Adaptor ProteinsCD8-Positive T-LymphocytesCell Line, TumorColorectal NeoplasmsDisease ProgressionFemaleHumansImmunologic SurveillanceInflammasomesInterleukin-18Killer Cells, NaturalMaleMiceMice, Inbred C57BLMice, KnockoutNADPH OxidasesNLR Family, Pyrin Domain-Containing 3 ProteinPhosphorylationReactive Oxygen SpeciesConceptsInflammasome activationColorectal cancerFive-year survival rateAssociated with colorectal cancer developmentAnti-tumor responsesCD8+ TColorectal cancer developmentColorectal cancer progressionApoptosis-associated speck-like proteinNK cellsImmune surveillanceRegulation of inflammasome activationSpeck-like proteinCancer developmentSurvival rateCancer progressionColorectal tumorigenesisPrecancerous cellsTransit amplifyingAIM2 inflammasome activationImmunoprecipitation-mass spectrometry analysisInflammasome responsesNCF4Modulating inflammasome activationROS levelsSLAMF7+ CD8+ T cells exhibit decreased anti-tumor responses in renal cell carcinoma
Wirth L, Hugaboom M, Street K, Ruthen N, Jegede O, Schindler N, McDermott D, Plimack E, Sosman J, Haas N, Hurwitz M, Hammers H, Signoretti S, Atkins M, Wu C, Braun D. SLAMF7+ CD8+ T cells exhibit decreased anti-tumor responses in renal cell carcinoma. The Journal Of Immunology 2024, 212: 1491_5876-1491_5876. DOI: 10.4049/jimmunol.212.supp.1491.5876.Peer-Reviewed Original ResearchCD8+ T cellsImmune-checkpoint inhibitorsRenal cell carcinomaCD8+ T-cell effector functionT cell effector functionT cellsCell carcinomaResistance to immune-checkpoint inhibitorsEffector functionsPopulation of CD8+ T cellsCD3+ T cellsTreatment of renal cell carcinomaHealthy human PBMCTumor-infiltrating lymphocytesAnti-tumor responsesPatient T cellsReduction of pro-inflammatory cytokinesAnti-tumor functionPro-inflammatory cytokinesSingle-cell transcriptome analysisNivolumab monotherapySLAMF7 expressionClinical benefitGranzyme BIFN-gLeukocyte-associated immunoglobulin-like receptor-1 blockade in combination with programmed death-ligand 1 targeting therapy mediates increased tumour control in mice
Singh A, Mommers-Elshof E, Vijver S, Jansen J, Gonder S, Lebbink R, Bihan D, Farndale R, Boon L, Langermann S, Leusen J, Flies D, Meyaard L, Pascoal Ramos M. Leukocyte-associated immunoglobulin-like receptor-1 blockade in combination with programmed death-ligand 1 targeting therapy mediates increased tumour control in mice. Cancer Immunology, Immunotherapy 2024, 73: 16. PMID: 38236251, PMCID: PMC10796629, DOI: 10.1007/s00262-023-03600-6.Peer-Reviewed Original ResearchConceptsLeukocyte-associated immunoglobulin-like receptor-1Increase tumor controlTumor controlAnti-programmed death-ligand 1Mouse modelT cells in vitroMouse T cells in vitroIncreased tumor clearanceAnti-tumor responsesDeath-ligand 1Immunocompetent mouse modelReduced tumor burdenControl tumor growthHumanized mouse modelIn vivo tumor modelsWild type miceAssociated with tumor developmentPD-L1Tumor burdenTumor clearanceConventional immunotherapyImmunocompetent miceTumor outgrowthTherapy responseTumor microenvironment
2023
Stem-like CD4 T differentiation controls CD8 T cell immunity or tolerance in cancer
Cardenas M, Prokhnevska N, Jansen C, Sobierajska E, Master V, Kissick H. Stem-like CD4 T differentiation controls CD8 T cell immunity or tolerance in cancer. The Journal Of Immunology 2023, 210: 86.04-86.04. DOI: 10.4049/jimmunol.210.supp.86.04.Peer-Reviewed Original ResearchTumor-draining lymph nodesAnti-tumor responsesCD4 T cellsEffector differentiationT cellsT-cell anti-tumor responseTumor-specific CD4 T cellsCD8 T cell responsesCD8 T cell immunityT cell effector differentiationCD4 T cell differentiationReduced tumor burdenT cell responsesT cell immunityDraining Lymph NodesT cell differentiationStem-like propertiesExpression of TCF1Tumor responseTumor burdenTreg differentiationLymph nodesCancer responseCD4 differentiationCD8
2021
640 Stem-like CD4 T cells in cancer
Cardenas M, Prokhnevska N, Jansen C, Master V, Kissick H. 640 Stem-like CD4 T cells in cancer. Journal For ImmunoTherapy Of Cancer 2021, 9: a669-a669. DOI: 10.1136/jitc-2021-sitc2021.640.Peer-Reviewed Original ResearchCD4 T cellsAnti-tumor responsesT cellsTH1-likeEffector subsetsEffector lineagesTumor-infiltrating CD4 T cellsVirus-specific CD4 T cellsInfiltrating CD4 T cellsResponses to tumor antigensFlow cytometryEx vivo functional analysisProstate cancer mouse modelCancer mouse modelGenes associated with stemnessEmory University HospitalPlasticity in vitroKidney cancer patientsHypothesis in vivoLCMV glycoproteinCD4 subsetTfh cellsTreg cellsEffector populationsTumor antigens
2020
Lassa-VSV chimeric virus targets and destroys human and mouse ovarian cancer by direct oncolytic action and by initiating an anti-tumor response
van den Pol A, Zhang X, Lima E, Pitruzzello M, Albayrak N, Alvero A, Davis J, Mor G. Lassa-VSV chimeric virus targets and destroys human and mouse ovarian cancer by direct oncolytic action and by initiating an anti-tumor response. Virology 2020, 555: 44-55. PMID: 33453650, PMCID: PMC8451984, DOI: 10.1016/j.virol.2020.10.009.Peer-Reviewed Original ResearchConceptsOvarian cancer cellsHuman ovarian cancer cellsLong-term survivalOvarian cancerCancer cellsTreatment of immunocompetent miceKill ovarian cancer cellsMouse ovarian cancer cellsTreatment of ovarian cancerAnti-tumor responsesImmunocompromised nude miceOncolytic actionImmunocompetent miceMetastatic spreadChemotherapeutic paclitaxelFemale cancersPoor survivalNude miceIntraperitoneal injectionCancer growthSurvival extensionVesicular stomatitis virusVSV glycoproteinCancerReduced neurotropismSurvival of subjects with recurrent glioblastoma receiving intratumoral administration of controlled IL-12 with limited exposure to dexamethasone.
Lukas R, Kurz S, Yu J, Landolfi J, Rao G, Amidei C, Buck J, Hadar N, Estupinan T, Miao J, Loewy J, Wang Y, Demars N, Gelb A, Cooper L. Survival of subjects with recurrent glioblastoma receiving intratumoral administration of controlled IL-12 with limited exposure to dexamethasone. Journal Of Clinical Oncology 2020, 38: 2564-2564. DOI: 10.1200/jco.2020.38.15_suppl.2564.Peer-Reviewed Original ResearchMedian overall survivalImpact of DexIL-12Intratumoral administrationIFN-gGrade III or IV gliomaImmune-mediated anti-tumor effectsLow-dose corticosteroidsAnti-tumor responsesSerum IL-12Time of resectionTumor response dataRecombinant IL-12Survival of subjectsAnti-tumor effectsExposure to dexamethasoneImmune system activationOverall survivalRecurrent glioblastomaIV gliomasControl edemaPreclinical modelsSafety profileInterleukin-12Historical controlsCD4 T cell phenotypes differentially modulate the CD8 T cell response in kidney cancer
Cardenas M, Prokhnevska N, Jansen C, Master V, Kissick H. CD4 T cell phenotypes differentially modulate the CD8 T cell response in kidney cancer. The Journal Of Immunology 2020, 204: 165.1-165.1. DOI: 10.4049/jimmunol.204.supp.165.1.Peer-Reviewed Original ResearchTumor-infiltrating CD4 T cellsInfiltrating CD4 T cellsCD8 T cell responsesCD4 T cellsAnti-tumor responsesT cell responsesCD8 T cell infiltrationT cellsKidney cancer patientsTumor-specific CD8 T-cell responsesTumor-infiltrating CD8 T cellsSubsets of CD4 T cellsCancer patientsCD8 T cell functionMaster transcription factor Foxp3CD8 T cell differentiationCD4 T cell phenotypeRenal cell carcinoma patientsResponse to immunotherapyCD8 T cellsT cell infiltrationT regulatory cellsT-cell phenotypeCell carcinoma patientsTranscription factor Foxp3Tumor-specific CD8 T cell activation in draining lymph nodes supports the anti-tumor CD8 T cell response
Prokhnevska N, Cardenas M, Jansen C, Valanparambil R, Master V, Sanda M, Kissick H. Tumor-specific CD8 T cell activation in draining lymph nodes supports the anti-tumor CD8 T cell response. The Journal Of Immunology 2020, 204: 165.5-165.5. DOI: 10.4049/jimmunol.204.supp.165.5.Peer-Reviewed Original ResearchTumor-specific CD8 T cellsCD8 T cellsStem-like CD8 T cellsCD8 T cell activationT cellsT cell activationEffector programLymph nodesCD8 T cell responsesImmune response to tumorsTumor-draining lymph nodesCD8 T cell infiltrationSubsets of CD8 T cellsAnti-tumor responsesT cell infiltrationResponse to tumorsTumor-specific antigensProstate cancer modelT cell responsesDraining Lymph NodesAcute viral infectionT cell immunologyCD8 responsesLCMV glycoproteinCD62L expression
2019
Evaluation of controlled IL-12 as monotherapy in subjects with recurrent GBM.
Lukas R, Chiocca E, Kurz S, Yu J, Landolfi J, Rao G, Barrett J, Buck J, Demars N, Smith A, Miao J, Zhou Q, Gelb A, Cooper L. Evaluation of controlled IL-12 as monotherapy in subjects with recurrent GBM. Journal Of Clinical Oncology 2019, 37: 2053-2053. DOI: 10.1200/jco.2019.37.15_suppl.2053.Peer-Reviewed Original ResearchCytokine release syndromeT cell ratioRecurrent glioblastomaIL-12Low-dose DexOverall survivalImmune-mediated anti-tumor effectsIntratumoral injection of AdImmune systemAnti-tumor responsesImproved overall survivalResponse to immunotherapySerum IL-12Replication-incompetent adenovirusCytotoxic T cellsInjection of AdAnti-tumor effectsDay 0Impact of DexFlu-like symptomsIL-12 productionInduce IL-12Biomarkers of OSRecurrent GBMIntratumoral injection
2017
Regression of devil facial tumour disease following immunotherapy in immunised Tasmanian devils
Tovar C, Pye R, Kreiss A, Cheng Y, Brown G, Darby J, Malley R, Siddle H, Skjødt K, Kaufman J, Silva A, Baz Morelli A, Papenfuss A, Corcoran L, Murphy J, Pearse M, Belov K, Lyons A, Woods G. Regression of devil facial tumour disease following immunotherapy in immunised Tasmanian devils. Scientific Reports 2017, 7: 43827. PMID: 28276463, PMCID: PMC5343465, DOI: 10.1038/srep43827.Peer-Reviewed Original ResearchConceptsEffective anti-tumor responseCancer cellsAnti-tumor immunityAnti-tumor responsesTumor diseaseDFTD cellsImmune-mediated regressionImmune cell infiltrationImmune cell responsesDevil facial tumour diseaseDFTD cancer cellsInduce humoral responsesTumor engraftmentMolecule expressionCell infiltrationDFTD tumorsHumoral responseAntibody responseMHC-IFacial tumour diseaseTumorCell responsesInfectious agentsImmunotherapyAllograft
2015
Adjuvant inhibition of iAPC function in the tumor microenvironment promotes therapeutic immunity in the setting of vaccination-induced T cell anti-tumor response
Antonios J, Soto H, Orpilla J, Shin N, Everson R, Liau L, Prins R. Adjuvant inhibition of iAPC function in the tumor microenvironment promotes therapeutic immunity in the setting of vaccination-induced T cell anti-tumor response. Journal For ImmunoTherapy Of Cancer 2015, 3: p393. PMCID: PMC4652564, DOI: 10.1186/2051-1426-3-s2-p393.Peer-Reviewed Original Research
2014
IT-01PD1/PDL1 INTERACTIONS MEDIATE SUPPRESSION OF ANTI-TUMOR IMMUNE ACTIVITY IN GLIOMA
Antonios J, Soto H, Harris R, Nathanson D, Sadeghi S, Ellingson B, Liau L, Prins R. IT-01PD1/PDL1 INTERACTIONS MEDIATE SUPPRESSION OF ANTI-TUMOR IMMUNE ACTIVITY IN GLIOMA. Neuro-Oncology 2014, 16: v110-v110. PMCID: PMC4218227, DOI: 10.1093/neuonc/nou258.1.Peer-Reviewed Original ResearchProgrammed death-1Tumor-infiltrating lymphocytesPost-implant dayCombination groupPD-1Tumor microenvironmentLymph nodesTreatment groupsEffective anti-tumor immune responseFACS analysisAnti-tumor immune activityAnti-tumor immune responseIncreased tumor-infiltrating lymphocytesAnti-PD1 mAbNegative costimulatory moleculesPD-1 mAbDendritic cell vaccinesAnti-tumor responsesImmunocompetent C57BL/6 miceTumor-bearing hemisphereDecreased tumor volumeGL261 glioma cellsCombined treatment groupAntitumor responseDeath-1
2002
Die Expression der ζ-Kette des T-Zell-Rezeptors als Prognosemarker bei Kopf-Hals-Karzinomen
Müller D, Lang S, Roskrow M, Wollenberg B. Die Expression der ζ-Kette des T-Zell-Rezeptors als Prognosemarker bei Kopf-Hals-Karzinomen. Laryngo-Rhino-Otologie 2002, 81: 516-520. PMID: 12173063, DOI: 10.1055/s-2002-33289.Peer-Reviewed Original ResearchConceptsTumor-infiltrating lymphocytesZeta chain expressionPeripheral blood lymphocytesT cell receptorTumor stageZeta chainCorrelated to clinical dataMechanisms of immune suppressionT cell receptor zeta chainSystemic immune defectsAnti-tumor responsesEarly tumor stageHigher tumor stageSquamous cell carcinomaHead and neckT cell activationFlow cytometric analysisSystemic immunomodulationImmune defectsInfiltrating lymphocytesClinical aggressivenessCell carcinomaImmune suppressionBlood lymphocytesSCCHN
1999
Herpes Simplex Virus (HSV)-Mediated ICAM-1 Gene Transfer Abrogates Tumorigenicity and Induces Anti-Tumor Immunity
D’Angelica M, Tung C, Allen P, Halterman M, Delman K, Delohery T, Klimstra D, Brownlee M, Federoff H, Fong Y. Herpes Simplex Virus (HSV)-Mediated ICAM-1 Gene Transfer Abrogates Tumorigenicity and Induces Anti-Tumor Immunity. Molecular Medicine 1999, 5: 606-616. PMID: 10551902, PMCID: PMC2230459, DOI: 10.1007/bf03402073.Peer-Reviewed Original ResearchConceptsIntercellular adhesion molecule-1Surface expression of adhesion moleculesExpression of adhesion moleculesTumor cellsCell surface expressionAmplicon vectorsAdhesion moleculesHigh-level cell surface expressionInduce anti-tumor immunityTransplantable rat hepatocellular carcinomaCell surface ICAM-1 expressionSurface expressionCell surface expression of adhesion moleculesExposure of tumor cellsExpression of intercellular adhesion molecule-1Immune response to cancerSurface ICAM-1 expressionAnti-tumor immunityAnti-tumor responsesParental tumor cellsHuman colorectal cancer cell linesHuman intercellular adhesion molecule-1Increased tumor expressionICAM-1 expressionHerpes simplex virus
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply